Abstract
Conjugates of antibodies with cytotoxic agents offer a targeted therapeutic strategy against cancer cells expressing target antigens. Several antibodies against various cancer cell-surface antigens have been conjugated with different cytotoxic agents that inhibit essential cellular targets such as microtubules or DNA. Antibody–cytotoxic agent conjugates (ACCs) against several types of cancer are currently in advanced stages of clinical trials and one, gemtuzumab ozogamicin (Mylotarg®), is approved for the treatment of acute myeloid leukemia. The linker group connecting the antibody to the cytotoxic agent is an important feature of the ACC, modulating the release of the active cytotoxic agent in the targeted cell. Several linker strategies employed for ACCs in current clinical trials include cleavable linkers with disulfide, hydrazone, lysosomal protease-substrate groups, and non-cleavable linkers. This chapter describes the methods of preparation of conjugates of antibodies with small-molecule cytotoxic agents (maytansinoids, calicheamicin, and auristatins) bearing different linkers. Methods to evaluate the in vitro cytotoxicity and in vivo anti-tumor efficacy of ACC are described in brief. Analytical methods are described to evaluate the mechanism of cellular processing of the ACCs with different linkers and the generation of the active metabolites.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ricart, A. D., and Tolcher, A. W. (2007) Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat. Clin. Pract. Oncol., 4, 245–255.
Chari., R. V. J. (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Accounts Chem. Res., 41, 98–107.
Lambert, J. M. (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol., 5, 543–549.
Wu, A. M., and Senter, P. D. (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol., 23, 1137–1146.
Hamann, P. R., Hinman, L. M., Beyer, C. F., et al. (2002) An anti-CD33 antibody–calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjugate Chem., 13, 4046.
Christiansen, J., and Rajasekaran, A. K. (2004) Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol. Cancer Ther., 3, 1493–1501.
Roguska, M. A., Petersen, J. T., Keddy, C. A., et al. (1994) Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. USA, 91, 969–973.
Mascelli, M. A., Zhou, H., Sweet, R., et al. (2007) Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J. Clin. Pharmacol., 47, 553–565.
Erickson, H. K., Park, P. U., Widdison, W. C., et al. (2006) Antibody–maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res., 66, 4426–4433.
Kung Sutherland, M. S., Sanderson, R. J., Gordon, K. A., et al. (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30–auristatin conjugates. J. Biol. Chem., 281, 10540–10547.
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., et al. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjugate Chem., 17, 114–124.
Widdison, W. C., Wilhelm, S. D., Cavanagh, E. E., et al. (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem., 49, 4392–4408.
Chari, R. V. J., Martell, B. A., Gross, J. L., et al. (1992) Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res., 52, 127–131.
Sanderson, R. J., Hering, M. A., James, S. F., et al. (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res., 11, 843–852.
Xie, H., and Blättler, W. A. (2006) In vivo behavior of antibody–drug conjugates for the targeted treatment of cancer. Expert Opin. Biol. Ther., 6, 281–291.
Kovtun, Y. V., Audette, C. A., Ye, Y. et al. (2006) Antibody–drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res., 66, 3214–3221.
Yang, J., Chen, H., Vlahov, I. R., Cheng, J.-X., and Low, P. S. (2006) Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl. Acad. Sci. USA, 103, 13872–13877.
DiJoseph, J. F., Armellino, D. C., Boghaert, E. R., et al. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood, 103, 1807–1814.
Hamann, P. R., Hinman, L. M., Beyer, C. F., et al. (2005) A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian cancer xenografts. Bioconjugate Chem., 16, 354–360.
Jordan, M. A., and Wilson, L. (2004) Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 4, 253–265.
Hinman, L. M., Hamann, P. R., Wallace, R., Menedez, A. T., Durr, F. E., and Upeslacis, J. (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res., 53, 3336–3342.
Anjaneyulu, P. S. R., and Staros, J. V. (1987) Reaction of N-hydroxysulfosuccinimide active esters. Int. J. Peptide Res., 30, 117–124.
Shipton, M., and Brocklehurst, K. (1978) Characterization of the papain centre by using two-protonic-state electrophiles as reactivity probes. Biochem. J., 171, 385–401.
Singh, R. (1994) A sensitive assay for maleimide groups. Bioconjugate Chem., 5, 348–351.
Lazar, A. C., Wang, L., Blättler, W. A., Amphlett, G., Lambert, J. M., and Zhang, W. (2005) Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun. Mass Spectrom., 19, 1806–1814.
Hamblett, K. J., Senter, P. D., Chace, D. F., et al. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody–drug conjugate. Clin. Cancer Res., 10, 7063–7070.
Che-Leung, L., Cerveny, C. G., Gordon, K. A., et al. (2004) Efficient elimination of B-lineage lymphomas by anti-CD20–auristatin conjugates. Clin. Cancer Res., 10, 7842–7851.
Hamann, P. R., Hinman, L. M., Hollander, I., et al. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody–calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem., 13, 47–58.
Dubowchik, G. M., Firestone, R. A., Padilla, L., et al. (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjugate Chem., 13, 855–869.
Acknowledgments
The authors thank Dr. Alexandru Lazar for providing the MS spectrum of an antibody–maytansinoid conjugate, Erin Maloney for providing the in vitro cytotoxicity data for anti-EGFR antibody–maytansinoid conjugates, and Carmela Provenzano for assistance with metabolite analysis.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Singh, R., Erickson, H.K. (2009). Antibody–Cytotoxic Agent Conjugates: Preparation and Characterization. In: Dimitrov, A. (eds) Therapeutic Antibodies. Methods in Molecular Biology™, vol 525. Humana Press. https://doi.org/10.1007/978-1-59745-554-1_23
Download citation
DOI: https://doi.org/10.1007/978-1-59745-554-1_23
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-934115-92-3
Online ISBN: 978-1-59745-554-1
eBook Packages: Springer Protocols